FIELD: biotechnology.
SUBSTANCE: described is a method for indirect determination of concentration of A-antigen of the industrial strain "VGNKI" of the causative agent of canine infectious hepatitis in raw material for cultural vaccines according to the cycle of quantitative assessment during amplification of the target region of the orf25-gene.
EFFECT: main advantages of the proposed invention are reduction of time for analysis of industrial raw material for production of cultural vaccines against CAV-1 by determining the concentration of the A-antigen of the strain "VGNKI" CAV-1 virus up to 3 hours (16 times faster than the prototype); elimination of contamination probability; high analytical, diagnostic sensitivity and specificity of the analysis; elimination of subjectivity factor of obtained results due to use of instrumentation for detection of results; increased reliability of the analysis due to the establishment of the relationship between the concentration of the A-antigen of the strain "VGNKI" CAV-1 and the cycle of quantitative assessment of the amplicons of the target region of the orf25-gene, presented in form of quadratic function with high values of accuracy of approximation and efficiency of amplification reaction.
3 cl, 2 dwg, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INDIRECTLY DETERMINING TITER OF INFECTIOUS ACTIVITY OF CANINE INFECTIOUS HEPATITIS VIRUS GENOTYPE CAV-1 IN RAW MATERIALS FOR CULTURED VACCINES USING REAL-TIME POLYMERASE CHAIN REACTION USING QUANTITATIVE ASSESSMENT CYCLE Cq | 2023 |
|
RU2812441C1 |
| METHOD FOR INDIRECT DETERMINATION OF CONCENTRATION OF RIBONUCLEOPROTEIN OF INDUSTRIAL STRAIN "RICH" OF CORONAVIRUS INFECTION AGENT IN RAW MATERIAL FOR CULTURAL VACCINES ACCORDING TO QUANTITATIVE ASSESSMENT CYCLE FOR AMPLICONS OF TARGET REGION OF M-GENE OF CORONAVIRUS | 2023 |
|
RU2821895C1 |
| METHOD FOR DIFFERENTIATION OF VACCINE STRAIN "VGNKI" OF ADENOVIRAL INFECTION CAUSATIVE AGENT FROM OTHER STRAINS AND FIELD ISOLATES BY ANALYZING MAXIMUM MELTING POINTS OF PCR PRODUCTS USING SUPERNOVA v605 TANDEM FLUORESCENT DYE | 2023 |
|
RU2825893C1 |
| METHOD FOR INDIRECT DETERMINATION OF TITRE OF INFECTIOUS ACTIVITY OF VACCINE STRAIN "PB-97" OF RABIES VIRUS IN RAW MATERIAL FOR VACCINE BASED ON ANALYSIS OF MELTING CURVES OF HIGH-RESOLUTION AMPLICONS USING THIRD GENERATION INTERCALATING DYE EVAGREEN | 2023 |
|
RU2830983C1 |
| METHOD OF INDIRECT DETERMINATION OF TITER OF INFECTIOUS ACTIVITY OF CANINE MASTADENOVIRUS IN RAW MATERIALS FOR VACCINES USING REAL-TIME PCR | 2023 |
|
RU2812858C1 |
| METHOD OF INDIRECT DETERMINING OF TITRE OF INFECTIOUS ACTIVITY OF CAUSATIVE AGENT OF CANINE DISTEMPER IN RAW MATERIALS FOR VACCINES USING METHOD OF REVERSE TRANSCRIPTION AND AMPLIFICATION REACTION IN REAL TIME | 2023 |
|
RU2815533C1 |
| METHOD FOR INDIRECT DETERMINATION OF TITER OF INFECTIOUS ACTIVITY OF CANINE MASTADENOVIRUS IN RAW MATERIALS FOR VACCINES USING REAL-TIME PCR | 2023 |
|
RU2808585C1 |
| METHOD FOR INDIRECT DETERMINATION OF FELINE CALICIVIRUS INFECTIOUS ACTIVITY TITRE IN NON-INACTIVATED RAW MATERIAL FOR CULTURAL VACCINES BY MEANS OF QUANTITATIVE REGISTRATION OF REACTION OF AMPLIFICATION OF ORF1-GENE SECTION OF VIRAL RNA | 2023 |
|
RU2821027C1 |
| METHOD FOR MEDIATED DETERMINATION OF RIBONUCLEOPROTEIN CONCENTRATION OF CANINE DISTEMPER AGENT IN RAW MATERIAL FOR VACCINES BY DATA OF QUANTITATIVE ASSESSMENT CYCLE DURING N-GENE AMPLIFICATION | 2023 |
|
RU2829837C1 |
| METHOD FOR DETERMINING TITRE OF INFECTIOUS ACTIVITY OF CANINE DISTEMPER AGENT IN RAW MATERIAL FOR MAKING CULTURE INACTIVATED VACCINES | 2024 |
|
RU2831062C1 |
